$MIRM
Mirum Pharmaceuticals, Inc.

2021 Q3 Form 10-Q Financial Statement

#000095017021000954 Filed on August 05, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2021 Q2 2020 Q2
Revenue $5.000M $11.00M $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $17.35M $13.35M $5.040M
YoY Change 202.84% 164.94% 105.71%
% of Gross Profit
Research & Development $30.47M $35.05M $18.56M
YoY Change 90.63% 88.89% 60.11%
% of Gross Profit
Depreciation & Amortization $84.00K $79.00K $70.00K
YoY Change 5.0% 12.86% 75.0%
% of Gross Profit
Operating Expenses $47.82M $48.40M $23.60M
YoY Change 120.22% 105.12% 68.14%
Operating Profit -$42.82M -$37.40M -$23.60M
YoY Change 97.2% 58.5% 68.14%
Interest Expense -$4.240M -$5.968M $410.0K
YoY Change -1866.67% -1555.61% -14.58%
% of Operating Profit
Other Income/Expense, Net -$35.00K -$514.0K -$56.00K
YoY Change 16.67% 817.86% -722.22%
Pretax Income -$47.10M -$43.88M -$23.25M
YoY Change 118.97% 88.76% 71.45%
Income Tax $9.000K $11.00K $3.000K
% Of Pretax Income
Net Earnings -$47.11M -$43.89M -$23.25M
YoY Change 119.05% 88.78% 71.51%
Net Earnings / Revenue -942.16% -399.04%
Basic Earnings Per Share -$1.55 -$1.45
Diluted Earnings Per Share -$1.551M -$1.45 -$930.0K
COMMON SHARES
Basic Shares Outstanding 30.52M 30.27M
Diluted Shares Outstanding 30.37M 30.27M

Balance Sheet

Concept 2021 Q3 2021 Q2 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $190.0M $223.9M $149.3M
YoY Change 42.08% 49.9% 77.38%
Cash & Equivalents $55.84M $91.94M $83.04M
Short-Term Investments $134.2M $131.9M $66.29M
Other Short-Term Assets $6.371M $4.515M $2.700M
YoY Change 44.8% 67.22% 285.71%
Inventory
Prepaid Expenses
Receivables $400.0K
Other Receivables $0.00
Total Short-Term Assets $196.8M $228.4M $152.1M
YoY Change 42.41% 50.14% 79.15%
LONG-TERM ASSETS
Property, Plant & Equipment $1.060M $1.127M $3.500M
YoY Change -68.82% -67.8% 150.0%
Goodwill
YoY Change
Intangibles $19.00M
YoY Change
Long-Term Investments $15.00M $14.99M $0.00
YoY Change -100.0%
Other Assets $1.641M $1.427M $200.0K
YoY Change 447.0% 613.5% -89.47%
Total Long-Term Assets $38.36M $19.30M $3.700M
YoY Change 936.81% 421.68% -80.93%
TOTAL ASSETS
Total Short-Term Assets $196.8M $228.4M $152.1M
Total Long-Term Assets $38.36M $19.30M $3.700M
Total Assets $235.2M $247.7M $155.8M
YoY Change 65.73% 58.97% 49.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.003M $5.380M $3.000M
YoY Change -3.79% 79.33% 30.43%
Accrued Expenses $43.85M $20.78M $13.60M
YoY Change 222.4% 52.76% 54.55%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $50.39M $29.03M $16.60M
YoY Change 168.02% 74.87% 49.55%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $19.00K $22.00K $3.000M
YoY Change -99.32% -99.27% 130.77%
Total Long-Term Liabilities $19.00K $22.00K $3.000M
YoY Change -99.32% -99.27% 130.77%
TOTAL LIABILITIES
Total Short-Term Liabilities $50.39M $29.03M $16.60M
Total Long-Term Liabilities $19.00K $22.00K $3.000M
Total Liabilities $178.8M $151.9M $19.60M
YoY Change 727.64% 675.16% 58.06%
SHAREHOLDERS EQUITY
Retained Earnings -$314.7M -$267.6M
YoY Change
Common Stock $371.1M $363.3M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $56.40M $95.74M $136.2M
YoY Change
Total Liabilities & Shareholders Equity $235.2M $247.7M $155.8M
YoY Change 65.73% 58.97% 49.43%

Cashflow Statement

Concept 2021 Q3 2021 Q2 2020 Q2
OPERATING ACTIVITIES
Net Income -$47.11M -$43.89M -$23.25M
YoY Change 119.05% 88.78% 71.51%
Depreciation, Depletion And Amortization $84.00K $79.00K $70.00K
YoY Change 5.0% 12.86% 75.0%
Cash From Operating Activities -$34.20M -$40.20M -$17.00M
YoY Change 96.0% 136.46% 112.23%
INVESTING ACTIVITIES
Capital Expenditures -$18.00K -$3.000K -$50.00K
YoY Change -64.0% -94.0%
Acquisitions
YoY Change
Other Investing Activities -$2.219M -$24.46M $28.03M
YoY Change -88.24% -187.25% -148.0%
Cash From Investing Activities -$2.237M -$24.46M $27.97M
YoY Change -88.17% -187.45% -147.89%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 345.0K 65.92M 20.00K
YoY Change -83.57% 329480.0% -99.97%
NET CHANGE
Cash From Operating Activities -34.20M -40.20M -17.00M
Cash From Investing Activities -2.237M -24.46M 27.97M
Cash From Financing Activities 345.0K 65.92M 20.00K
Net Change In Cash -36.09M 1.258M 10.99M
YoY Change 5.35% -88.55% -243.47%
FREE CASH FLOW
Cash From Operating Activities -$34.20M -$40.20M -$17.00M
Capital Expenditures -$18.00K -$3.000K -$50.00K
Free Cash Flow -$34.18M -$40.20M -$16.95M
YoY Change 96.46% 137.14% 111.61%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseMember
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2021Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001759425
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseMember
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Amendment Flag
AmendmentFlag
false
CY2020Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseMember
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38981
dei Entity Registrant Name
EntityRegistrantName
Mirum Pharmaceuticals, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-1281555
dei Entity Address Address Line1
EntityAddressAddressLine1
950 Tower Lane, Suite 1050,
dei Entity Address City Or Town
EntityAddressCityOrTown
Foster City
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94404
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
667-4085
dei Security12b Title
Security12bTitle
Common stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
MIRM
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
30515833
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
91938000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
142086000
CY2021Q2 us-gaap Short Term Investments
ShortTermInvestments
131913000
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
89734000
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4515000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4530000
CY2021Q2 us-gaap Assets Current
AssetsCurrent
228366000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
236350000
CY2021Q2 us-gaap Long Term Investments
LongTermInvestments
14990000
CY2020Q4 us-gaap Long Term Investments
LongTermInvestments
0
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1127000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1293000
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1758000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1949000
CY2021Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1427000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1272000
CY2021Q2 us-gaap Assets
Assets
247668000
CY2020Q4 us-gaap Assets
Assets
240864000
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
5380000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3151000
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
20775000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13411000
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
671000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
636000
CY2021Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
2202000
CY2020Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
1264000
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
29028000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
18462000
CY2021Q2 mirm Revenue Interest Liability Noncurrent
RevenueInterestLiabilityNoncurrent
120610000
CY2020Q4 mirm Revenue Interest Liability Noncurrent
RevenueInterestLiabilityNoncurrent
47651000
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2271000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2627000
CY2021Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
22000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
29000
CY2021Q2 us-gaap Liabilities
Liabilities
151931000
CY2020Q4 us-gaap Liabilities
Liabilities
68769000
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30506433
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30317173
CY2021Q2 mirm Common Stock Shares Outstanding Subject To Repurchase
CommonStockSharesOutstandingSubjectToRepurchase
189260
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30032600
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29776544
CY2020Q4 mirm Common Stock Shares Outstanding Subject To Repurchase
CommonStockSharesOutstandingSubjectToRepurchase
256056
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
3000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2021Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
363344000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
345180000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-267597000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-173171000
CY2021Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-13000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
83000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
95737000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
172095000
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
247668000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
240864000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11000000
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11000000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2021Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
35048000
CY2020Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
18555000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
73182000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
35895000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13353000
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5042000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22832000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9734000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
48401000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
23597000
us-gaap Operating Expenses
OperatingExpenses
96014000
us-gaap Operating Expenses
OperatingExpenses
45629000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-37401000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-23597000
us-gaap Operating Income Loss
OperatingIncomeLoss
-85014000
us-gaap Operating Income Loss
OperatingIncomeLoss
-45629000
CY2021Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
80000
CY2020Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
405000
us-gaap Investment Income Interest
InvestmentIncomeInterest
229000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1154000
CY2021Q2 mirm Other Nonoperating Interest Expense
OtherNonoperatingInterestExpense
4776000
CY2020Q2 mirm Other Nonoperating Interest Expense
OtherNonoperatingInterestExpense
0
mirm Other Nonoperating Interest Expense
OtherNonoperatingInterestExpense
8157000
mirm Other Nonoperating Interest Expense
OtherNonoperatingInterestExpense
0
CY2021Q2 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues
1272000
CY2020Q2 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues
0
us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues
938000
us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues
0
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-514000
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-56000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-530000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-79000
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-43883000
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-23248000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-94410000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-44554000
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
11000
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
16000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-43894000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-23251000
us-gaap Net Income Loss
NetIncomeLoss
-94426000
us-gaap Net Income Loss
NetIncomeLoss
-44561000
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.45
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.93
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.13
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.79
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
30274749
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
25056123
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
30190352
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24880387
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-43894000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-23251000
us-gaap Net Income Loss
NetIncomeLoss
-94426000
us-gaap Net Income Loss
NetIncomeLoss
-44561000
CY2021Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-16000
CY2020Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
339000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-90000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
190000
CY2021Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
3000
CY2020Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
3000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-6000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-1000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-43907000
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22909000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-94522000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-44372000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
172095000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
80000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
7038000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5285000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-50532000
CY2021Q1 us-gaap Other Comprehensive Income Loss Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
-83000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
133883000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
295000
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
643000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4823000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-43894000
CY2021Q2 us-gaap Other Comprehensive Income Loss Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
-13000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
95737000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
130349000
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
44659000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2573000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-21310000
CY2020Q1 us-gaap Other Comprehensive Income Loss Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
-153000
CY2020Q2 us-gaap Other Comprehensive Income Loss Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
342000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
136208000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
156118000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
25000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2974000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-23251000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
61734000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
6914000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
44659000
mirm Proceeds Of Issuance Costs Related To The Revenue Interest Liability
ProceedsOfIssuanceCostsRelatedToTheRevenueInterestLiability
64574000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1018000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
25000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
72506000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases Sales Issuances Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements
-938000
mirm Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-171000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-65409000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-35345000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
70100000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
61900000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-103000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
36000
mirm Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-94000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
162000
mirm Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities
9856000
mirm Proceeds From Paydowns Of Investments
ProceedsFromPaydownsOfInvestments
2000000
mirm Proceeds From Paydowns Of Investments
ProceedsFromPaydownsOfInvestments
14005000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
129336000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
14020000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
151000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-57239000
mirm Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities
3486000
mirm Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-321000
us-gaap Profit Loss
ProfitLoss
-94426000
us-gaap Profit Loss
ProfitLoss
-44561000
us-gaap Share Based Compensation
ShareBasedCompensation
10108000
us-gaap Share Based Compensation
ShareBasedCompensation
5547000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
169000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
143000
mirm Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
191000
mirm Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
160000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
22000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
7000
mirm Non Cash Interest Expense On Revenue Interest Purchase Agreement
NonCashInterestExpenseOnRevenueInterestPurchaseAgreement
8157000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
44684000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-6000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-1000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-50148000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
71072000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
142086000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
11970000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
91938000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
83042000
us-gaap Operating Lease Payments
OperatingLeasePayments
426000
us-gaap Operating Lease Payments
OperatingLeasePayments
216000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
42000
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2018-05-02
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-267600000
CY2021Q2 mirm Cash Cash Equivalents And Short And Long Term Investments
CashCashEquivalentsAndShortAndLongTermInvestments
238800000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:24.5pt;text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:24.5pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the financial statements and accompanying notes. The most significant estimates in the Company’s unaudited condensed consolidated financial statements relate to the revenue interest liability, accrued research and development expenses, the valuation of derivative liabilities, equity award compensation and the valuation allowance of deferred tax assets resulting from net operating losses. These estimates and assumptions are based upon historical experience, knowledge of current events and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results could differ materially from those estimates.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7138234
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5903227
CY2021Q2 mirm Cash Equivalents And Available For Sale Securities Debt Securities
CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities
230984000
CY2021Q2 mirm Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis
CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
230993000
CY2021Q2 mirm Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2021Q2 mirm Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
9000
CY2021Q2 mirm Cash Equivalents And Available For Sale Securities Debt Securities
CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities
230984000
CY2021Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
84081000
CY2021Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
131913000
CY2021Q2 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
14990000
CY2020Q4 mirm Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis
CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
229432000
CY2020Q4 mirm Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
82000
CY2020Q4 mirm Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1000
CY2020Q4 mirm Cash Equivalents And Available For Sale Securities Debt Securities
CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities
229513000
CY2020Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
139779000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
89734000
CY2020Q4 mirm Cash Equivalents And Available For Sale Securities Debt Securities
CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities
229513000
CY2021Q2 us-gaap Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value
AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue
131913000
CY2021Q2 mirm Held To Maturity Securities Debt Maturities Rolling Year One Through Two Fair Value
HeldToMaturitySecuritiesDebtMaturitiesRollingYearOneThroughTwoFairValue
14990000
CY2021Q2 us-gaap Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
146903000
CY2020Q2 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2021Q2 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2021Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0
CY2020Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0
us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0
us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0
CY2021Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y7M6D
CY2021Q2 mirm Accrued Milestones Current
AccruedMilestonesCurrent
2000000
CY2020Q4 mirm Accrued Milestones Current
AccruedMilestonesCurrent
0
CY2021Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3459000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2157000
CY2021Q2 mirm Accrued Contract Manufacturing And Non Clinical Costs Current
AccruedContractManufacturingAndNonClinicalCostsCurrent
5732000
CY2020Q4 mirm Accrued Contract Manufacturing And Non Clinical Costs Current
AccruedContractManufacturingAndNonClinicalCostsCurrent
2780000
CY2021Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4530000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4801000
CY2019Q1 us-gaap Area Of Land
AreaOfLand
5600
us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
The lease term is approximately four years with an option to extend the term for one five-year term, which at the time was not reasonably assured of exercise and therefore, not included in the lease term.
CY2021Q2 mirm Accrued Clinical Trials Current
AccruedClinicalTrialsCurrent
5054000
CY2020Q4 mirm Accrued Clinical Trials Current
AccruedClinicalTrialsCurrent
3673000
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
20775000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13411000
CY2020Q4 mirm Revenue Interest Liability
RevenueInterestLiability
47651000
CY2021Q1 mirm Interest Expense Accrued
InterestExpenseAccrued
3381000
CY2021Q1 mirm Debt Issuances Costs Capitalized
DebtIssuancesCostsCapitalized
172000
CY2021Q1 mirm Revenue Interest Liability
RevenueInterestLiability
50860000
CY2021Q2 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
65000000
CY2019Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P4Y
CY2019Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2019Q1 mirm Tenant Improvement Allowance
TenantImprovementAllowance
400000
CY2021Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.080
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1800000
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
2900000
CY2021Q2 mirm Interest Expense Accrued
InterestExpenseAccrued
4776000
CY2021Q2 mirm Debt Issuances Costs Capitalized
DebtIssuancesCostsCapitalized
26000
CY2021Q2 mirm Revenue Interest Liability
RevenueInterestLiability
120610000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
437000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
888000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
916000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
925000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
232000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3398000
CY2021Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
456000
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
2942000
CY2021Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
200000
CY2020Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
200000
us-gaap Operating Lease Expense
OperatingLeaseExpense
300000
us-gaap Operating Lease Expense
OperatingLeaseExpense
300000
CY2020Q3 mirm Maximum Amount Of Sale Covered In Shelf Registration Statement
MaximumAmountOfSaleCoveredInShelfRegistrationStatement
300000000.0
CY2021Q2 mirm Common Stock Aggregate Offering Price Remaining
CommonStockAggregateOfferingPriceRemaining
68400000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5547000
CY2021Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
9484950
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
8343673
us-gaap Share Based Goods And Nonemployee Services Transaction Modification Of Terms Incremental Compensation Cost
ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost
300000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4823000
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2974000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10108000

Files In Submission

Name View Source Status
0000950170-21-000954-index-headers.html Edgar Link pending
0000950170-21-000954-index.html Edgar Link pending
0000950170-21-000954.txt Edgar Link pending
0000950170-21-000954-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
mirm-20210630.htm Edgar Link pending
mirm-20210630.xsd Edgar Link pending
mirm-20210630ex31_1.htm Edgar Link pending
mirm-20210630ex31_2.htm Edgar Link pending
mirm-20210630ex32_1.htm Edgar Link pending
mirm-20210630ex32_2.htm Edgar Link pending
mirm-20210630_cal.xml Edgar Link unprocessable
mirm-20210630_def.xml Edgar Link unprocessable
mirm-20210630_htm.xml Edgar Link completed
mirm-20210630_lab.xml Edgar Link unprocessable
mirm-20210630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending